383 related articles for article (PubMed ID: 19500141)
1. N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy.
Baskurt M; Okcun B; Abaci O; Dogan GM; Kilickesmez K; Ozkan AA; Ersanli M; Gurmen T
Eur J Clin Invest; 2009 Sep; 39(9):793-9. PubMed ID: 19500141
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
Bilasy ME; Oraby MA; Ismail HM; Maklady FA
J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
[TBL] [Abstract][Full Text] [Related]
3. Use of NaCl saline hydration and N-Acetyl Cysteine to prevent contrast induced nephropathy in different populations of patients at high and low risk undergoing coronary artery angiography.
Calabrò P; Bianchi R; Caprile M; Sordelli C; Cappelli Bigazzi M; Palmieri R; Gigantino G; Limongelli G; Capozzi G; Cuomo S; Calabrò R
Minerva Cardioangiol; 2010 Feb; 58(1):35-40. PubMed ID: 20145594
[TBL] [Abstract][Full Text] [Related]
4. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.
Maioli M; Toso A; Leoncini M; Gallopin M; Tedeschi D; Micheletti C; Bellandi F
J Am Coll Cardiol; 2008 Aug; 52(8):599-604. PubMed ID: 18702961
[TBL] [Abstract][Full Text] [Related]
5. N-acetylcysteine and sodium bicarbonate versus N-acetylcysteine and standard hydration for the prevention of radiocontrast-induced nephropathy following coronary angiography.
Schmidt P; Pang D; Nykamp D; Knowlton G; Jia H
Ann Pharmacother; 2007 Jan; 41(1):46-50. PubMed ID: 17190844
[TBL] [Abstract][Full Text] [Related]
6. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial.
Ozcan EE; Guneri S; Akdeniz B; Akyildiz IZ; Senaslan O; Baris N; Aslan O; Badak O
Am Heart J; 2007 Sep; 154(3):539-44. PubMed ID: 17719303
[TBL] [Abstract][Full Text] [Related]
7. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
[TBL] [Abstract][Full Text] [Related]
8. [Prevention of contrast-induced nephropathy using cardiac catheterization combined with hydration, oral N-acetylcysteine, sodium bicarbonate and iso-osmolar contrast agents].
Hoshino A; Enomoto S; Kawahito H; Kurata H; Nakahara Y; Nakamura T
J Cardiol; 2007 Aug; 50(2):119-26. PubMed ID: 17802695
[TBL] [Abstract][Full Text] [Related]
9. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics.
Coyle LC; Rodriguez A; Jeschke RE; Simon-Lee A; Abbott KC; Taylor AJ
Am Heart J; 2006 May; 151(5):1032.e9-12. PubMed ID: 16644332
[TBL] [Abstract][Full Text] [Related]
10. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature.
Goldenberg I; Shechter M; Matetzky S; Jonas M; Adam M; Pres H; Elian D; Agranat O; Schwammenthal E; Guetta V
Eur Heart J; 2004 Feb; 25(3):212-8. PubMed ID: 14972421
[TBL] [Abstract][Full Text] [Related]
11. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
[TBL] [Abstract][Full Text] [Related]
12. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study.
Ferrario F; Barone MT; Landoni G; Genderini A; Heidemperger M; Trezzi M; Piccaluga E; Danna P; Scorza D
Nephrol Dial Transplant; 2009 Oct; 24(10):3103-7. PubMed ID: 19549691
[TBL] [Abstract][Full Text] [Related]
13. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
[TBL] [Abstract][Full Text] [Related]
14. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention.
Seyon RA; Jensen LA; Ferguson IA; Williams RG
Heart Lung; 2007; 36(3):195-204. PubMed ID: 17509426
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy.
Kinbara T; Hayano T; Ohtani N; Furutani Y; Moritani K; Matsuzaki M
J Cardiol; 2010 Mar; 55(2):174-9. PubMed ID: 20206069
[TBL] [Abstract][Full Text] [Related]
17. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial).
Lee SW; Kim WJ; Kim YH; Park SW; Park DW; Yun SC; Lee JY; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Suh J; Cho YH; Lee NH; Cheong SS; Yoo SY; Lee BK; Lee SG; Hyon MS; Shin WY; Lee SW; Jang JS; Park SJ
Am J Cardiol; 2011 May; 107(10):1447-52. PubMed ID: 21420063
[TBL] [Abstract][Full Text] [Related]
18. Sodium bicarbonate versus normal saline for protection against contrast nephropathy.
Budhiraja P; Chen Z; Popovtzer M
Ren Fail; 2009; 31(2):118-23. PubMed ID: 19212908
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.
Toso A; Maioli M; Leoncini M; Gallopin M; Tedeschi D; Micheletti C; Manzone C; Amato M; Bellandi F
Am J Cardiol; 2010 Feb; 105(3):288-92. PubMed ID: 20102936
[TBL] [Abstract][Full Text] [Related]
20. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention.
Ochoa A; Pellizzon G; Addala S; Grines C; Isayenko Y; Boura J; Rempinski D; O'Neill W; Kahn J
J Interv Cardiol; 2004 Jun; 17(3):159-65. PubMed ID: 15209578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
